This week, on the heels of Aduhelm’s FDA approval, the agency granted breakthrough status to two more prospective new Alzheimer’s treatments, Eli Lilly &…
Drugmaker Cassava believes its experimental Alzheimer’s therapy, which sent the company’s stock values surging with a recent phase 2 study announcement, could beat Biogen’s…
Researchers have set out to study whether the concurrent use of two common types of drugs for people with Alzheimer’s could end up creating…
Biogen has agreed to buy an experimental Alzheimer’s and Parkinson’s treatment from Pfizer, the company announced Monday. In the agreed deal, Biogen will pay…